Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JATT NASDAQ:PRTG NASDAQ:SCYX NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJATTJATT Acquisition$1.42-4.1%$1.32$7.80▼$12.38$140.76MN/A41,322 shs232,648 shsPRTGPortage Biotech$9.30-6.7%$6.40$2.10▼$23.01$9.75M0.2444,140 shs121,342 shsSCYXSCYNEXIS$0.87-1.1%$0.76$0.66▼$1.90$33.75M1.64246,658 shs288,424 shsTPSTTempest Therapeutics$7.36+4.7%$7.13$5.33▼$28.34$27.10M-1.9387,882 shs43,191 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJATTJATT Acquisition-4.05%-5.33%+5.19%+17.36%-62.53%PRTGPortage Biotech0.00%+71.59%+51.96%+13.97%+189.00%SCYXSCYNEXIS0.00%+27.00%+23.57%-8.66%-53.49%TPSTTempest Therapeutics0.00%-1.74%0.00%+13.41%-59.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APRTGPortage Biotech0.3148 of 5 stars0.04.00.00.00.01.70.0SCYXSCYNEXIS0.507 of 5 stars0.04.00.00.00.60.80.6TPSTTempest Therapeutics2.128 of 5 stars3.35.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJATTJATT Acquisition 0.00N/AN/AN/APRTGPortage Biotech 0.00N/AN/AN/ASCYXSCYNEXIS 0.00N/AN/AN/ATPSTTempest Therapeutics 2.50Moderate Buy$30.00307.61% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJATTJATT AcquisitionN/AN/A$0.05 per share27.08($0.53) per shareN/APRTGPortage BiotechN/AN/AN/AN/A($0.79) per shareN/ASCYXSCYNEXIS$3.75M9.00N/AN/A$1.45 per share0.60TPSTTempest TherapeuticsN/AN/AN/AN/A$5.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/APRTGPortage Biotech-$6.77M-$41.65N/A∞N/AN/AN/AN/A8/26/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.56N/A17.30N/A-1,030.04%-53.47%-32.86%8/14/2025 (Estimated)TPSTTempest Therapeutics-$41.84M-$17.98N/AN/AN/AN/A-305.51%-119.74%8/14/2025 (Estimated)Latest PRTG, SCYX, TPST, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SCYXSCYNEXIS-$0.23N/AN/AN/A$0.15 millionN/A8/14/2025Q2 2025TPSTTempest Therapeutics-$3.23N/AN/AN/AN/AN/A5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million5/13/2025Q1 2025TPSTTempest Therapeutics-$3.71-$3.16+$0.55-$3.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJATTJATT AcquisitionN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJATTJATT AcquisitionN/A0.150.15PRTGPortage BiotechN/A2.022.02SCYXSCYNEXISN/A5.835.83TPSTTempest TherapeuticsN/A1.701.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJATTJATT Acquisition47.97%PRTGPortage Biotech13.36%SCYXSCYNEXIS54.37%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipJATTJATT Acquisition20.00%PRTGPortage Biotech42.07%SCYXSCYNEXIS4.86%TPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionablePRTGPortage Biotech61.05 millionN/AOptionableSCYXSCYNEXIS6039.02 million37.12 millionOptionableTPSTTempest Therapeutics203.68 million3.51 millionOptionablePRTG, SCYX, TPST, and JATT HeadlinesRecent News About These CompaniesMorpheus-Liver Study: A New Horizon in Advanced Liver Cancer TreatmentAugust 4, 2025 | tipranks.comTempest Therapeutics’ Promising Advances in Liver Cancer TreatmentJuly 3, 2025 | tipranks.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in China - NasdaqJuly 2, 2025 | nasdaq.comTempest Therapeutics Receives NMPA Approval for Pivotal Trial of Amezalpat in Hepatocellular Carcinoma Treatment in ChinaJune 30, 2025 | quiverquant.comQTempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in ChinaJune 30, 2025 | globenewswire.comTPST - Tempest Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMTPST Tempest Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comTempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | quiverquant.comQTempest Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | globenewswire.comTempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic AlternativesJune 7, 2025 | marketwatch.comTempest Therapeutics Shares Up, Executive Team Enters Into Consulting AgreementsJune 7, 2025 | marketwatch.comTPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer TherapyJune 6, 2025 | zacks.comTempest Therapeutics stock rises on EMA Orphan Drug DesignationJune 5, 2025 | au.investing.comTempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCCJune 5, 2025 | globenewswire.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finance.yahoo.comTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comTempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual MeetingApril 28, 2025 | globenewswire.comDual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous PolyposisApril 25, 2025 | empr.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTG, SCYX, TPST, and JATT Company DescriptionsJATT Acquisition NYSE:JATT$1.42 -0.06 (-4.05%) As of 08/8/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Portage Biotech NASDAQ:PRTG$9.30 -0.67 (-6.72%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$8.87 -0.43 (-4.58%) As of 08/8/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.SCYNEXIS NASDAQ:SCYX$0.86 -0.01 (-1.14%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.84 -0.02 (-2.66%) As of 08/8/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Tempest Therapeutics NASDAQ:TPST$7.36 +0.33 (+4.69%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.44 +0.07 (+1.02%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
